CEUS is a safer, less expensive option for diagnosing focal liver disease.
Contrast-enhanced ultrasound (CEUS) is a safer, less costly option than CT and MRI when it comes to the accurate diagnosis of some types of liver cancer, according to recent research.
In a study published recently in Hepatoma Research, a team of investigators from the University of Calgary outlined some the unique advantages that CEUS offers when characterizing focal liver disease.
“CEUS provides for the determination of malignancy and allows excellent differential diagnosis of a focal liver mass,” said lead study author Stephanie Wilson, M.D., chair of the University of Calgary radiology department. “CEUS regularly resolves an indeterminate result on CT/MRI and is exceptional as a problem-solving tool in liver imaging.”
Routinely, she said, CEUS demonstrates comparable performance to CT and MRI with the characterization and prediction of malignancy.
To determine the details of CEUS’ capabilities, Wilson’s team analyzed the results of a multi-center trial that included 1,349 patients. The study, they said, revealed no statistically significant difference between CEUS and spiral CT in differentiating between benign and malignant liver tumors, as well as tumor specification. The team also examined a meta-analysis of 21 studies that showed CEUS has 88-percent sensitivity, 81-percent specificity, and a diagnostic odds ratio of 38.62. Those studies also showed no statistical differences between contrast-enhanced MRI and contrast-enhanced CT.
In particular, the team noted, CEUS offers several advantages:
Ultimately, the team concluded, CEUS can play a beneficial and effective role in liver cancer diagnostic imaging.
“CEUS has many similarities to contrast-enhanced CT/MRI, but also unique and valuable differences,” they said, “most showing the additional benefit of inclusion of CEUS with CT and MR for liver imaging.”
Emerging AI Algorithm Shows Promise for Abbreviated Breast MRI in Multicenter Study
April 25th 2025An artificial intelligence algorithm for dynamic contrast-enhanced breast MRI offered a 93.9 percent AUC for breast cancer detection, and a 92.3 percent sensitivity in BI-RADS 3 cases, according to new research presented at the Society for Breast Imaging (SBI) conference.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Can Abbreviated Breast MRI Have an Impact in Assessing Post-Neoadjuvant Chemotherapy Response?
April 24th 2025New research presented at the Society for Breast Imaging (SBI) conference suggests that abbreviated MRI is comparable to full MRI in assessing pathologic complete response to neoadjuvant chemotherapy for breast cancer.